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Abstract
SIRT1 is a NAD+-dependent deacetylase that plays important roles in many cellular processes. 
SIRT1 activity is uniquely controlled by a C-terminal regulatory segment (CTR). Here we present 
crystal structures of the catalytic domain of human SIRT1 in complex with the CTR in an open 
apo form and a closed conformation in complex with a cofactor and a pseudo-substrate peptide. 
The catalytic domain adopts the canonical sirtuin fold. The CTR forms a β hairpin structure that 
complements the β sheet of the NAD+-binding domain, covering an essentially invariant, 
hydrophobic surface. The apo form adopts a distinct open conformation, in which the smaller 
subdomain of SIRT1 undergoes a rotation with respect to the larger NAD+-binding subdomain. A 
biochemical analysis identifies key residues in the active site, an inhibitory role for the CTR, and 
distinct structural features of the CTR that mediate binding and inhibition of the SIRT1 catalytic 
domain.
Keywords
X-ray crystallography; conformational plasticity; enzyme peptide substrate interaction; mutational 
analysis; enzyme regulation
Introduction
Sirtuins are a large family of protein-modifying enzymes highly conserved throughout 
bacteria, archaea, and eukaryotes. The founding member of the sirtuin family, silent 
information regulator 2 (Sir2), was first identified through a genetic screen in 
Saccharomyces cerevisiae as necessary for silencing of the mating-type information locus, 
HM.1 Three additional sirtuin genes were subsequently discovered in S. cerevisiae,2,3 the 
products of which collectively act along with Sir2 to silence transcription at telomeres and 
rDNA clusters as well as HM loci.4–7 Later work showed Sir2 and its homologs to function 
primarily as nicotinamide adenine dinucleotide (NAD+)-dependent deacetylases,8–10 with 
specific family members reported to possess mono-ADP ribosyl transferase,11–16 
demalonylase, or desuccinylase activity.17
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In the sirtuin deacetylation reaction, the substrate acetyl group is transferred onto the ribose 
moiety of NAD+, generating nicotinamide (NAM) and 2′-O-acetyl-adenosine 
disphosphoribose (2-O′-AADPR).18 While the details of this reaction are still a matter of 
debate, a proposed mechanism that proceeds through an adenosine diphosphoribose 
(ADPR)-peptidyl-imidate intermediate is consistent with available biochemical data.19 
Crystal structures of a number of sirtuin family members have provided insight into 
substrate and cofactor binding as well as catalysis.11,20–40
The mammalian genome encodes seven different sirtuins (SIRT1-7), with varying 
subcellular localizations and chemical activities.17,41 The direct human homolog of S. 
cerevisiae Sir2 is SIRT1. SIRT1 deacetylates a wide range of substrates, including p53, NF-
κB, FOXO transcription factors, and PGC-1α, with roles in cellular processes ranging from 
energy metabolism to cell survival.42 As such, SIRT1 is implicated in a wide range of 
human diseases and is a prominent therapeutic target.
Despite progress over the last decade, relatively little is known about the regulatory 
mechanism of SIRT1. Like all sirtuins, SIRT1 is strongly inhibited by NAM through a base-
exchange mechanism that reforms cleaved NAD+.43 Active Regulator of SIRT1 (AROS) 
and Deleted in Breast Cancer 1 (DBC1) have been identified as endogenous proteins that 
promote or inhibit SIRT1 activity, respectively.44–46 Additionally, various regions in the 
long and mostly unstructured N- and C-termini that flank the SIRT1 catalytic domain have 
been shown to affect SIRT1 deacetylation activity.47,48
To shed light on the regulation of human SIRT1 activity, we have determined the crystal 
structure of SIRT1 in complex with its C-terminal regulatory segment (CTR) in its apo form 
and in a quaternary complex with the NAD+ hydrolysis product ADPR and a substrate-
mimicking peptide at 2.65 Å and 1.85 Å resolution, respectively. The structures reveal that 
the CTR binds at the lower edge of the larger NAD+-binding domain, complementing the 
central parallel β sheet of its Rossmann fold. The substrate-bound closed state completely 
encapsulates the cofactor and forms a binding site with a hydrophobic tunnel for the 
substrate residue that leads to a shielded active site in the interior of the enzyme. The overall 
conformation and mode of substrate binding confirms previous predictions of how human 
SIRT1 interacts with peptide substrates. In the absence of bound cofactor and substrate, the 
smaller domain of the SIRT1 catalytic domain undergoes a striking ~25° rotation that is 
accompanied by an ~15 Å shift of the residues of the domain, generating a wide open 
interdomain groove, while the larger domain and CTR interface remain mostly unchanged. 
A mutational analysis identifies key residues for enzymatic activity of SIRT1 and supports 
the previously proposed imidate reaction mechanism. Further biochemical experiments 
establish an inhibitory role for the CTR and define corresponding binding and inhibitory 
regions. Our results provide a promising avenue for the development of novel SIRT1 
activators that take advantage of the distinct features of the catalytic domain-CTR interface.
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Results
Reconstitution of active SIRT1 and structure determination
Our attempts to express various fragments of the catalytic domain of Homo sapiens SIRT1 
in bacteria yielded protein prone to aggregation. Based on previous findings that a C-
terminal region is required for SIRT1 activity,47,48 we generated a series of expression 
constructs for various C-terminal fragments that were tested for their ability to interact with 
the catalytic domain. We identified residues 234 to 510 and 641 to 665 of the catalytic 
domain (CAT) and the C-terminal regulatory segment (CTR), respectively, which formed a 
heterodimeric complex as determined by size exclusion chromatography (Fig. 1a, b). 
Coexpression of the two SIRT1 fragments greatly improved the solubility, stability, and 
behavior of the catalytic domain in solution (Tables S1 and S2). An analysis by size 
exclusion chromatography coupled to multiangle light scattering (SEC-MALS) revealed that 
the heterodimer is monomeric in solution with a measured molecular mass of 34.8 kDa 
(theoretical 35.1 kDa) (Fig. 1c). We refer to this complex as the SIRT1CAT•CTR 
heterodimer in the following text.
Crystals of the apo form of SIRT1CAT•CTR appeared in the tetragonal space group P43212, 
contained four copies of the heterodimer in the asymmetric unit, and diffracted to 2.65 Å 
resolution. We also obtained crystals of the SIRT1CAT•CTR heterodimer in the presence of 
NAD+ in the trigonal space group P3221 that diffracted to 1.85 Å and contained one copy of 
the complex in the asymmetric unit. Both structures were solved by single-wavelength 
anomalous dispersion (SAD) using anomalous X-ray diffraction data obtained by taking 
advantage of the endogenous bound Zn2+ ions. The final models essentially contain all 
residues of both protein fragments in the substrate- and cofactor-bound states and possess 
excellent stereochemical parameters. The models were refined to Rwork and Rfree values of 
23.0 % and 26.5 % (apo form) and 16.8 % and 18.9 % (quaternary complex), respectively. 
For details of the data collection and refinement statistics, see Table 1.
Structural overview
The SIRT1 catalytic domain possesses the canonical sirtuin fold as first described in the 
archaeal Sir2•Af1•NAD+ complex structure,25 composed of a larger NAD+-binding 
subdomain with a Rossmann fold and a smaller subdomain composed of a helical module 
and a Zn2+-binding module, which are both insertions in the NAD+-binding domain.
The 25-residue CTR can be divided into a larger N-terminal region, followed by a shorter C-
terminal extension, which each make distinct interactions with the catalytic domain. The N-
terminal region forms a β hairpin that complements the central parallel β sheet of the 
Rossmann fold domain with two additional strands. This interface between the catalytic 
domain and the CTR is large, hydrophobic, and highly conserved in evolution. The C-
terminal CTR extension forms additional contacts with the helical module that are only 
observed in one of the two crystallized states.
Despite the fact that we obtained crystals of SIRT1CAT•CTR in the presence of NAD+, the 
heterodimer is bound to adenosine diphosphate ribose (ADPR), likely a product of non-
enzymatic NAD+ hydrolysis or disorder of the nicotinamide moiety. Surprisingly, the 
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heterodimer engages the extended tail region of the catalytic domain of an adjacent molecule 
in the crystal lattice, yielding a quaternary substrate-mimicking complex. When compared to 
the substrate- and cofactor-bound state of the heterodimer, the apo form adopts a wide-open 
conformation, in which the smaller subdomain undergoes a striking ~25° rotation, leading to 
the disruption of all interactions between the large and small subdomains and the formation 
of an ~15 Å wide interdomain cleft. As such, we refer to these two states as “open” and 
“closed” throughout the text. This conformational change leads to the exposure of the 
hydrophobic interior and the cofactor-binding site of the enzyme in the open state, and to the 
disruption of the substrate-binding groove.
The structure of SIRT1 catalytic domain
The SIRT1 catalytic core is composed of 277 residues and is divided into two subdomains, a 
larger NAD+-binding domain, which adopts a Rossmann fold, and a smaller domain, which 
is generated by two insertions in the NAD+-binding domain, a helical module (residues 269 
to 324) and a Zn2+-binding module (residues 362 to 419) (Figs. 2 and S1). The NAD+-
binding domain is composed of a central six-stranded parallel β sheet, comprising strands 
β1-3 and β7-9, and eight α helices, αA, αB, αG, αH, and αJ-M that pack against the β sheet 
core of the domain (Figs. 2 and S1). The helical module is composed of four α helices, αC-
F, and the Zn2+-binding module is composed of three β strands, β4-6, and a single α helix, 
αI. The Zn2+ ion is tetrahedrally coordinated by four invariant cysteine residues, Cys371, 
Cys374, Cys395, and Cys398. An extensive hydrophobic interface holds the helical and 
Zn2+-binding modules together, generating the tightly associated small subdomain of the 
catalytic core. In total, 40 residues, primarily of helices αD, αE, αF and the αI-β6 region, are 
involved in the interaction between the two modules, burying ~1,800 Å2 of surface area. The 
relative orientation and the interaction between the large and small domains are dramatically 
different in the open and closed states and are described in detail below.
Interaction between SIRT1CAT and the CTR
The larger N-terminal region of the CTR (residues 641 to 653) forms a β hairpin that binds 
to the lower edge of the NAD+-binding domain of SIRT1CAT, complementing the central 
six-stranded parallel β sheet of the Rossmann fold with two additional β strands, β10 and β11 
(Fig. 3). The β hairpin covers an essentially invariant hydrophobic patch, which is generated 
by residues of helices αA and αL, β strand β9, and the β8-β9 connector, forming an entirely 
hydrophobic interface that is composed of 17 and 11 residues of SIRT1CAT and CTR, 
respectively. In total, the two proteins bury ~1,150 Å2 of surface area. The CTR-binding site 
on the Rossmann fold is located close to the binding site for the adenine ring of NAD+ 
(termed the A pocket) and the CTR directly interacts with Arg466 of the β8-β9 loop, which 
forms extensive van der Waals contacts with one face of the adenine ring (Fig. 3). CTR 
binding does not alter the conformation of the catalytic domain, as evidenced by a root-
mean-square deviation (RMSD) of ~0.6 Å (276 Cα atoms) between the closed state and a 
recently determined structure of the catalytic domain in the absence of the CTR in complex 
with a small molecule inhibitor (Fig. S2a).39 In the closed state the C-terminal extension of 
the CTR (residues 654 to 660) undergoes a conformational change and forms additional 
interactions with the helical module (see below).
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Substrate interaction
To shed light on the conformational changes that SIRT1 undergoes upon cofactor binding, 
we also crystallized SIRT1CAT•CTR in the presence of NAD+. While we were unable to 
obtain crystals of SIRT1CAT•CTR in the presence of an acetylated substrate peptide, the 
structure surprisingly revealed that SIRT1CAT•CTR engages the extended seven-residue tail 
segment (residues 504 to 510) of an adjacent heterodimer in the crystal (Figs. 2 and S3a). 
The sequence of the tail segment, PVKLSEI, resembles the sequence and chemical nature of 
the SIRT1 substrate region in p53, HKKAcLMF, but possesses a hydrophobic leucine 
residue in place of the substrate acetyl-lysine residue that is inserted into the hydrophobic 
tunnel which leads to the internal active site of the enzyme (Fig. 4). The tail region binds 
SIRT1CAT•CTR by forming anti-parallel β sheet-like interactions on one side with the β7-
αK connector (residues 444 to 446) of the Rossmann fold domain and on the other side with 
the Phe-Gly-Glu (FGE) motif (residues 414 to 416) of the Zn2+-binding module (Fig. 4a, b). 
While substrate binding is primarily achieved by backbone hydrogen bonding, the residues 
of both regions are evolutionarily highly conserved, suggesting that different substrates 
interact with SIRT1 in a similar manner. Overall, the trans binding of the pseudo substrate 
tail region to SIRT1CAT•CTR faithfully mimics the “β staple” interaction that was 
previously observed in the structure of the non-physiological ternary complex between the 
thermophilic bacterium Thermotoga maritima TmSir2, ADPR, and a six-residue p53 peptide 
(Fig. 4).29 Confirmation of these results will require additional structural analysis of a 
SIRT1 substrate interaction.
While we crystallized SIRT1CAT•CTR in the presence of NAD+, the electron density 
unambiguously establishes that only the NAD+ hydrolysis product ADPR, which lacks 
nicotinamide, is bound (Fig. 4c). The presence of ADPR may be the result of slow non-
enzymatic hydrolysis of NAD+, or disorder of the nicotinamide moiety.49,50 The ADPR 
molecule is well ordered and makes extensive hydrogen bond and van der Waals 
interactions with the Rossmann fold domain, essentially identical to those seen in other 
previously determined sirtuin structures.20,21,27,29,30,39,51
In order to determine whether the trans interaction between the tail region of one 
SIRT1CAT•CTR with the substrate-binding site of another SIRT1CAT•CTR may be 
physiologically relevant, we tested whether SIRT1CAT•CTR is capable of forming dimers or 
other higher order oligomers in solution in the presence of NAD+. A SEC-MALS analysis 
revealed that SIRT1CAT•CTR remains monomeric in the presence of 5 mM NAD+ with no 
higher order oligomeric states detectable at concentrations as high as 20 mg/ml (Fig. S4). 
Further studies are required to address whether the tail region is important for 
oligomerization and regulation of SIRT1 in vivo, especially in the context of the full-length 
protein and oligomeric substrates.
Conformational changes of SIRT1 upon cofactor and substrate binding
We have determined the structure of human SIRT1 in two different states, the apo form of 
SIRT1CAT•CTR (open state), and a quaternary complex of SIRT1CAT•CTR with ADPR and 
a pseudo-substrate peptide (closed state) (Fig. 2). The four copies of the apo form in the 
asymmetric unit make different crystal packing interactions and align with a maximum 
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RMSD of ~0.5 Å2 over 286 Cα atoms, suggesting that SIRT1 possesses a distinct open 
conformation that is independent of crystal packing interactions (Fig. S3b). Moreover, the 
tail region that engages an adjacent SIRT1CAT•CTR in the closed state is disordered in all 
four copies of the open state, further demonstrating that it is not a structural element of the 
catalytic core.
A comparison between the open and closed states reveals the conformational changes that 
SIRT1 undergoes upon substrate and cofactor binding. The larger NAD+-binding domain, 
together with the N-terminal region of the CTR, does not undergo any major structural 
changes, as illustrated by an RMSD of ~0.5 Å2 over 170 Cα atoms (Fig. 5). In the closed 
state, the smaller domain forms an extensive interface with the larger domain, resulting in 
the complete closure of the interdomain groove and the formation of a hydrophobic tunnel 
that engages the substrate residue (Fig. 5d). In the absence of cofactor and substrate, SIRT1 
adopts an open state with a large interdomain groove, exposing the invariant hydrophobic 
interior and the NAD+-binding site (Fig. 5e and 5f). Overall, the smaller domain rotates by 
~25° with a maximum displacement of the domain atoms of ~15 Å. Altogether, the two 
modules that generate the small subdomain rotate essentially as a rigid body with only minor 
changes to the backbone and side-chain conformations as illustrated by an RMSD of ~1.3 
Å2 over 114 Cα atoms. Notable exceptions are the αB-αC interdomain connector and helix 
αC, which undergo an additional conformational change to form a lid over the cofactor, 
leading to its encapsulation, and the FGE motif of the β6-αJ connector which forms the 
upper β strand of the substrate-binding β staple. The lower β strand of the β staple that is 
formed by the β7-αK connector of the Rossmann fold only undergoes minor conformational 
changes. Whereas the N-terminal region of the CTR is static, the C-terminal extension 
adopts a distinct conformation in the closed state that allows for the formation of a salt 
bridge between Glu656 and Arg276 of the helical module.
Taken together, SIRT1 undergoes dramatic conformational changes upon substrate and 
cofactor binding. The open state observed here for SIRT1 is substantially more open than 
previously determined apo states of other sirtuins, suggesting that each member of the 
sirtuin family adopts a unique open state, while the closed states are essentially identical.
Mutational analysis
To determine the importance of various residues for the deacetylase activity of SIRT1, we 
generated mutants based on the structures presented here, a multi-species sequence 
alignment (Fig. S1), and previous biochemical and structural work.18 We mutated seven 
residues in the SIRT1 active site that are evolutionarily invariant in bacteria, archaea, and 
eukaryotes, and which have been shown in other sirtuins to either capture the nicotinamide 
released from the NAD+ cofactor (Ser265, Asn346, Ile347, and Asp348), bind and orient the 
NAD+ cofactor (Gln345), mediate the interaction with the substrate peptide (Phe414), or are 
catalytically required to abstract a proton from the activated NAD+ (His363) (Fig. 6a). To 
clarify the role of the CTR in SIRT1 regulation, we generated an additional five mutants in 
the SIRT1CAT-CTR interface. These included two residues of the catalytic domain which 
contact both the CTR and the adenine ring of ADPR (Arg466 and Asp481), two residues 
that form a salt bridge between the catalytic domain and the CTR in the closed conformation 
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(Arg276 and Glu656), as well as a truncation of the twelve C-terminal residues of the CTR 
(CTR3ΔC) (Fig. 6b). Of the twelve mutants, ten were indistinguishable from the wild-type 
SIRT1CAT•CTR heterodimer in their behavior on a gel filtration column. Two mutants, 
N346A and D348N, were insoluble following recombinant expression and could therefore 
not be tested. The ten SIRT1CAT•CTR mutants (S265A, R276A, Q345A, I347A, H363A, 
F414A, R466A, D481A, E656A, and CTR3ΔC) along with the crystallized wild-type 
SIRT1CAT•CTR heterodimer and SIRT1CAT in the absence of the CTR, were tested in two 
different in vitro deacetylase activity assays that employ modified, acetylated p53-based 
peptides (Fig. S5). The results of both assays were consistent and are summarized in Fig. 6c.
All five active site mutants display either weak (S265A) or no deacetylase activity (Q345A, 
I347A, H363A, and F414A), demonstrating their involvement in the catalytic reaction. 
These results are in line with previous studies on other sirtuins and support the previously 
proposed ADPR-peptidyl-imidate mechanism for the deacetylation reaction.19 The two 
mutants R466A and D481A, in which the wild-type residues are sandwiched between the 
ADPR and the C-terminal extension of the CTR, yield proteins with substantially reduced 
catalytic activity, highlighting their role in co-factor binding.
SIRT1CAT alone, being prone to aggregation, showed variability in activity between 
experiments, and, hence, any results obtained in the absence of CTR need to be interpreted 
with caution. However, despite its fragility, SIRT1CAT in isolation consistently displayed 
higher activity compared to the SIRT1CAT•CTR heterodimer, indicating an inhibiting effect 
of the CTR. This inhibitory effect is mediated by the C-terminal 10 residues of the CTR 
(CTR3ΔC), as evidenced by the loss of SIRT1CAT inhibition in the SIRT1CAT•CTR3ΔC 
heterodimer. Similar results were obtained for the R276A and E656A mutants, indicating 
that the salt bridge between these residues is the primary determinant of inhibition by the 
CTR. The R276A mutant did not significantly increase the activity of SIRT1CAT in the 
absence of the CTR, suggesting that the primary means through which this residue regulates 
activity is through its interaction with the CTR. Moreover, both Arg276 and Glu656 are 
invariant in mammalian SIRT1 enzymes, indicating that this regulatory feature is 
evolutionarily conserved.
Biochemical analysis of the SIRT1CAT-CTR interaction
As a result of the observed inhibitory effect of the CTR on SIRT1 activity, we sought to 
determine whether the CTR is a persistent structural feature of the catalytic domain, as 
previously observed for the tail region of the catalytic domain of S. cerevisiae Sir2 (Fig. 
S2b).40 Due to the fact that SIRT1CAT is prone to aggregation, we were unable to determine 
the dissociation constant between SIRT1CAT and the CTR by isothermal titration 
calorimetry. However, we tested whether the CTR can be displaced from the 
SIRT1CAT•CTR complex. To test this hypothesis we incubated the SIRT1CAT•CTR 
heterodimer with SUMO-tagged CTR and monitored exchange by size-exclusion 
chromatography. Indeed, a SUMO-CTR can displace the CTR from a preformed 
SIRT1CAT•CTR complex (Fig. 7a). We additionally incubated SUMO-CTR with a GST-
CTR•SIRT1CAT complex and performed pull-down experiments. Similarly, increasing 
amounts of SUMO-CTR resulted in decreasing amounts of pulled-down SIRT1CAT (Fig. 
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7b). To further probe the SIRT1CAT•CTR interaction, we designed mutations at the binding 
interface and assayed their ability to form a complex in a GST pull-down assay (Fig. 7c). 
Mutation of three hydrophobic CTR residues (Phe644, Tyr650, Ile651) to alanine or 
aspartate abolished CTR binding to SIRT1CAT. Mutation of Tyr642 to alanine resulted in 
reduced binding that was completely lost upon mutation to aspartate. Based on these results 
we conclude that the CTR binding may represent a regulated interaction to inhibit SIRT1 
activity.
Thermostability
During our in vitro deacetylation assays, we noticed a rapid decay of enzymatic activity and 
a variability between different purifications for SIRT1CAT, which was not observed for 
SIRT1CAT•CTR. In addition, we obtained substantially lower yields for SIRT1CAT in 
isolation relative to the coexpressed SIRT1CAT•CTR complex (Table S2). These findings 
prompted us to explore whether the CTR stabilizes the catalytic domain. We found that the 
SIRT1CAT•CTR heterodimer was substantially more resistant to temperature denaturation 
than SIRT1CAT in isolation or in the presence of a non-interacting CTR mutant. Specifically, 
whereas SIRT1CAT already begins to precipitate at 30 °C, the SIRT1CAT•CTR heterodimer 
remains completely soluble up to 39 °C (Fig. 8a). In line with these results, the isolated 
SIRT1 catalytic domain displays an almost complete loss of activity when incubated for two 
hours at 37 °C, whereas activity is maintained for the SIRT1CAT•CTR heterodimer (Fig. 8b). 
These data support a stabilizing role for the CTR on the SIRT1 catalytic domain and provide 
an explanation for previous difficulties in characterizing the biochemical and structural 
properties of SIRT1.
Discussion
We have determined the crystal structure of the catalytic domain of human SIRT1 in 
complex with a C-terminal regulatory segment (CTR) in two different conformations, the 
apo form of the heterodimer and a quaternary complex with ADPR and a pseudo-substrate, 
the tail of another SIRT1CAT that mimics a p53 substrate sequence. The comparison of the 
two structures reveals that the interdomain angle and association between the two domains 
of the catalytic core are dramatically different upon substrate and cofactor binding. Further 
conformational changes occur in the C-terminal extension of the CTR that inhibit the 
activity of the catalytic domain.
The observation that sirtuins engage unique regions flanking the canonical catalytic domain 
has been made previously in the structure of S. cerevisiae Hst2.26 In that case, a homotrimer 
has been observed in the crystal and in solution, which is mediated by an N-terminal region 
that interacts with an adjacent catalytic domain in a substrate-mimicking fashion. In human 
SIRT1, a C-terminal seven-residue tail segment that is disordered in the apo state engages an 
adjacent molecule in the NAD+-bound closed state. The overall mode of interaction 
faithfully mimics the interaction between a p53 substrate peptide, the main difference being 
that a hydrophobic leucine residue, instead of an acetylated lysine residue, is inserted into 
the hydrophobic tunnel that leads to the internal active site of the enzyme. The substrate-
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mimicking interaction observed here might be useful for the development of competitive 
SIRT1 inhibitors.
Our biochemical analysis expands upon recent findings on the regulatory nature of the 
CTR.47,48 Namely, we establish an inhibitory role for the CTR primarily mediated by the 
formation of a salt bridge between the C-terminal extension and the helical module that is 
only observed in our closed SIRT1CAT•CTR•ADPR•Substrate structure. We propose that 
this interaction tunes the activity of the catalytic domain by influencing the conformational 
changes that are required for substrate and cofactor turnover (Fig. 9). This is in contrast to 
recent work stating that the CTR is required for SIRT1 activity.47 However, we believe this 
conclusion may be a result of the propensity of the SIRT1CAT to aggregate in solution in the 
absence of the CTR. Despite the overall hydrophobic nature and large surface of the 
SIRT1CAT-CTR interface, we demonstrate that the SIRT1CAT-CTR interaction is not merely 
a structural augmentation of the catalytic domain, but rather possesses the necessary 
characteristics of a regulated interaction. Such a regulatory mechanism could involve the 
phosphorylation of the CTR, which contains four predicted phosphorylation sites (Tyr650, 
Tyr658, Ser659, and Ser661).52
Our structural and functional analysis presented here allow us to propose a model for the 
regulation of SIRT1 and provide the framework for the development of potent and selective 
SIRT1 activity modulators that promise to be a new therapeutic avenue for the treatment of a 
variety of human diseases.
Methods
Protein expression and purification
DNA fragments of H. sapiens SIRT1 were amplified by PCR and cloned into the vector 
pGEX-6P-1 (GE Healthcare), a modified pET28a vector (Novagen) that contained a 
PreScission protease site after the N-terminal hexahistidine tag (pET28a-PreS),53 and a 
modified pET28b vector that contained an N-terminal hexahistidine-SUMO tag (pET28b-
SUMO).54 SIRT1 mutants were generated by QuikChange mutagenesis (Stratagene) and 
confirmed by DNA sequencing. Details of all constructs are listed in Table S1.
All proteins were expressed in E. coli BL21-CodonPlus(DE3)-RIL cells (Stratagene) grown 
in LB media supplemented with appropriate antibiotics. Protein expression was induced at 
an OD600 of approximately 0.6 with 500 μM IPTG for 16–18 hours at 18 °C. Cells were 
harvested by centrifugation.
The SIRT1CAT•CTR complex and all SIRT1CAT•CTR mutants were made by coexpressing 
SIRT1CAT in pET28a-PreS and CTR in pGEX-6P-1 (Table S2). Cells were resuspended in a 
buffer containing 20 mM Tris, pH 8.0, 100 mM NaCl, 5 mM DTT, 2 μM bovine lung 
aprotinin (Sigma), and complete EDTA-free protease inhibitor cocktail (Roche), and flash 
frozen in liquid nitrogen. Thawed cells were lysed with a cell disrupter (Avestin) and the 
lysate was centrifuged for 1 hour at 40,000 x g. The cleared lysate was applied to a 
glutathione sepharose column equilibrated in 20 mM Tris, pH 8.0, 100 mM NaCl, and 5 mM 
DTT (GE Healthcare) and eluted via a glutathione gradient. Pooled fractions were cleaved 
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with PreScission protease (GE Healthcare) for 12 hours and further purified over an 
additional glutathione sepharose column. The protein was concentrated and injected onto a 
HiLoad 16/60 Superdex 75 column (GE Healthcare) equilibrated in 20 mM Tris, pH 8.0, 
100 mM NaCl, and 5 mM DTT. Pooled fractions were concentrated to 12.5 mg/ml and used 
in subsequent crystallization trials or for in vitro activity assays. The GST-tagged 
SIRT1CAT•CTR used in pull-down experiments was purified in the same manner, omitting 
the protease cleavage step.
SIRT1CAT in isolation, and all SIRT1CAT mutants, were made by expressing SIRT1CAT in 
pET28a-PreS. Cells were resuspended in a buffer containing 20 mM Tris, pH 8.0, 500 mM 
NaCl, 5 mM β-mercaptoethanol, 2 μM bovine lung aprotinin (Sigma), and complete EDTA-
free protease inhibitor cocktail (Roche), and flash frozen in liquid nitrogen. Thawed cells 
were lysed with a cell disrupter and the lysate was centrifuged for 1 hour at 40,000 x g. The 
cleared lysate was loaded onto a Ni-NTA column (Qiagen) and eluted via an imidazole 
gradient. Protein-containing fractions were pooled, dialyzed against a buffer containing 20 
mM Tris, pH 8.0, 100 mM NaCl, and 5 mM DTT, and cleaved with PreScission protease for 
12 hours. Cleaved protein was bound to a HiTrap Q HP (GE Healthcare) column and eluted 
via a NaCl gradient, concentrated, and injected onto a HiLoad 16/60 Superdex 75 column 
equilibrated in 20 mM Tris, pH 8.0, 100 mM NaCl, and 5 mM DTT. SUMO-CTR, and all 
SUMO-CTR mutants, followed the same purification as SIRT1CAT in isolation.
Structure determination and refinement
Crystals of SIRT1CAT•CTR were grown at 21 °C in hanging drops containing 1 μl of the 
protein and 1 μl of a reservoir solution consisting of 100 mM Tris, pH 7.4, and 11 % PEG 
20,000. Crystals grew in the tetragonal space group P43212 and reached a maximum size of 
approximately 700 μm × 100 μm × 100 μm within a week. Crystals of 
SIRT1CAT•CTR•ADPR were grown in similar conditions in the presence of a two-fold 
molar excess of NAD+ (Sigma), grew in the trigonal space group P3221, and reached a 
maximum size of approximately 300 μm × 100 μm × 100 μm within two weeks. For cryo 
protection, crystals were stabilized in 100 mM Tris, pH 7.4, 13 % PEG 20,000, and 20 % 
ethylene glycol (added in 1 % increments). X-ray diffraction data were collected at 100 K at 
beamline 12-2 at the Stanford Synchrotron Radiation Lightsource (SSRL), and at beamline 
8.2.2 at the Advanced Light Source (ALS) at Lawrence Berkeley National Laboratory 
(LBNL). X-ray intensities were processed using the HKL2000 denzo/scalepack package.55
Both structures were solved by single wavelength anomalous dispersion (SAD) using X-ray 
diffraction data collected utilizing the anomalous scattering of the endogenous Zn2+ ions. 
Heavy metal sites were identified with SHELXD.56 Phases were calculated in SHARP,57 
followed by density modification in DM58 with solvent flattening, histogram matching, and 
NCS averaging. This procedure yielded excellent electron density maps that allowed for the 
placement of the coordinates of the S. cerevisiae Sir2 (PDB code 2HJH). Iterative rounds of 
model building and refinement in Coot59 and PHENIX60 yielded final models in which all 
residues of both protein fragments were resolved in the substrate- and cofactor-bound states 
with the exception of the C-terminal tails of the catalytic domain (residues 503 to 510; apo 
state) and CTR (residues 661 to 665; both states). The final Rwork and Rfree values of the apo 
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and the substrate- and cofactor-bound states of SIRT1 were 23.0 % and 26.5 % and 15.6 % 
and 18.7 %, respectively. Both models possess excellent stereochemical parameters with no 
residues in the generously allowed or disallowed regions of the Ramachandran plot as 
assessed with PROCHECK and MolProbity.61,62 For details of the data collection and 
refinement statistics, see Table 1.
Analytical size-exclusion chromatography
Protein interaction experiments were carried out on a Superdex 200 10/300 GL gel filtration 
column (GE Healthcare) equilibrated in a buffer containing 20 mM Tris, pH 8.0, 100 mM 
NaCl, and 5 mM DTT. SIRT1CAT and the SIRT1CAT•CTR heterodimer were mixed with an 
approximately two-fold molar excess of SUMO-tagged CTR, and incubated for 30 minutes 
on ice. Complex formation was monitored by injection of the preincubated proteins and the 
individual components in isolation, and confirmed by SDS-PAGE of the protein-containing 
fractions, followed by Coomassie brilliant blue staining.
GST pull-down assays
12.5 μg of a GST-CTR•SIRT1CAT complex was mixed with varying amounts of SUMO-
CTR, added to approximately 20 μl of Glutathione Sepharose beads (GE Healthcare) 
equilibrated in a buffer containing 20 mM Tris, pH 8.0, 100 mM NaCl, and 5 mM DTT, and 
incubated on ice for 1 hour. The beads were isolated via centrifugation at 750 x g, and 
washed five times by resuspension in 200 μL of buffer, followed by subsequent 
centrifugation. All samples were analyzed by SDS-PAGE, followed by Coomassie brilliant 
blue staining. For CTR mutational analysis, lysate from E. coli transformed with the 
indicated constructs was added to 250 μl of beads.
Deacetylase activity assays
Deacetylase activity of SIRT1 proteins was determined using the SIRT-Glo (Promega) and 
Fluor de Lys SIRT1 (Enzo) assays, according to the manufacturers’ protocols. SIRT-Glo 
reactions were carried out with 1 μM of pure protein and were incubated at room 
temperature for 45 minutes. Fluor de Lys reactions contained 0.2 μM pure protein, 75 μM 
substrate, and 3 mM NAD+, were incubated at 37 °C for 45 minutes, and developed at room 
temperature for 1 hour. Luminescence (SIRT-Glo) and fluorescence (Fluor de Lys) were 
measured using a Flexstation-3 microplate reader (Molecular Devices) and autofluorescence 
was subtracted.
Thermostability Assay
15 μg of SIRT1CAT in isolation or mixed with an approximately two fold molar excess of 
SUMO-CTR or SUMO-CTRY650D, I651D was incubated at the indicated temperatures for 1 
hour. Samples were pelleted by centrifugation at 30,000 x g and analyzed by SDS-PAGE 
followed by Coomassie brilliant blue staining.
Multiangle light scattering
Purified proteins were characterized by multiangle light scattering following size-exclusion 
chromatography.63 Proteins were injected onto a Superdex 200 10/300 GL gel filtration 
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chromatography column equilibrated in a buffer containing 20 mM Tris, pH 8.0, 100 mM 
NaCl, and 5 mM DTT. The chromatography system was connected in series with an 18-
angle light-scattering detector (DAWN HELEOS II; Wyatt Technology), a dynamic light-
scattering detector (DynaPro Nanostar; Wyatt Technology), and a refractive index detector 
(Optilab t-rEX; Wyatt Technology). Data were collected every 1 second at a flow rate of 0.5 
mL/min at 25 °C. Data analysis was carried out using the program ASTRA 6, yielding the 
molar mass and mass distribution (polydispersity) of the sample.
Illustration and figures
The sequence alignment of SIRT1 was generated using ClustalX and colored with 
Alscript.64,65 Figures were generated using PyMOL (www.pymol.org). Electrostatic 
potential was calculated with Adaptive Poisson-Boltzmann Solver (APBS) software.66
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
1. Crystal structures of the human SIRT1 catalytic domain in complex with its 
CTR
2. Conformational changes upon substrate and co-factor binding elucidated
3. Mutagenesis identifies key residues for catalysis and CTR-mediated inhibition
4. CTR binding pocket provides opportunity for the development of novel 
therapeutics
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Fig. 1. 
Biochemical analysis of the SIRT1CAT•CTR complex. (a) Domain structure. Blue, NAD+-
binding domain; yellow, helical module; green, Zn2+-binding module; red, pseudo-substrate 
peptide (T, tail); purple, C-terminal regulatory segment (CTR); grey, predicted unstructured 
regions (U). The bars above the domain structure mark the crystallized fragments. (b) Size-
exclusion chromatography interaction analysis of SIRT1CAT with SUMO-CTR. The 
analyzed proteins and complexes are indicated in each gel filtration profile. For analysis of 
complex formation, the SUMO-CTR was mixed at approximately 2-fold molar excess of 
SIRT1CAT and injected onto a Superdex 200 10/300 GL gel filtration column. Gray bars and 
colored lines designate the analyzed fractions. Molecular mass standards and the positions of 
the proteins are indicated. The asterisk indicates a degraded SUMO-CTR fragment. (c) 
Multiangle light scattering (MALS) analysis of the SIRT1CAT•CTR heterodimer. The 
differential refractive index is plotted against the elution volume from a Superdex 200 
10/300 GL gel filtration column and overlaid with the determined molecular mass for the 
peak.
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Fig. 2. 
Structure of H. sapiens SIRT1. (a) Structure of the quaternary 
SIRT1CAT•CTR•ADPR•Substrate complex in ribbon representation, colored as in Fig. 1a. 
(b) Structure of the SIRT1CAT•CTR heterodimer, displayed in the same orientation as in 
panel (b).90°-rotated views are shown on the right. See also Figs. S1 and S3.
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Fig. 3. 
Interface between SIRT1CAT and the C-terminal regulatory segment. Ribbon representation 
of the interface between the SIRT1CAT and the CTR colored according to Fig. 1a. The inset 
illustrates the position of the CTR-binding site on the larger NAD+-binding domain and its 
interacting residues and is expanded on the right. Residues participating in the interface are 
shown in ball-and-stick representation.
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Fig. 4. 
Structural comparison of H. sapiens SIRT1 to a bacterial Sir2 substrate complex. (a) A 
ribbon representation of SIRT1CAT•CTR•ADPR•Substrate (left, colored as in Fig. 1a), T. 
maritima Sir2 in complex with a p53 peptide (middle), and a superposition of the two 
(right). (b) A stick representation of the pseudo-substrate and p53 substrate peptide from the 
corresponding structures in panel (a) and their superposition. The PDB code of the TmSir2 
structure is 2H59.29 (c) Final 2|fo|-|fc| electron density map around the ADPR and pseudo-
substrate peptide rendered at 1.0 σ. See also Fig. S4.
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Fig. 5. 
Structural comparison of open and closed SIRT1 states. (a) Ribbon representations of the 
closed SIRT1CAT•CTR•ADPR•Substrate state, (b) the open SIRT1CAT•CTR conformation, 
and (c) a superposition of the two. (d, e) Surface representations of the corresponding 
structures in panels (a) and (b). A 90°-rotated view is shown on the right. (f) A model of 
pseudo-substrate peptide and ADPR binding to the open SIRT1CAT•CTR state. A 90°-
rotated view is shown on the right. See also Fig. S2.
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Fig. 6. 
Mutational analysis. (a) Ribbon representation of the SIRT1CAT•CTR•ADPR•Substrate 
complex, with a stick representation of all mutated active side residues. The Zn2+-binding 
and helical modules were removed for clarity. (b) Ribbon representation of the 
SIRT1CAT•CTR•ADPR•Substrate complex, with a stick representation of all mutated 
SIRT1CAT-CTR interface residues. (c) Deacetylase activity of SIRT1 proteins and mutants 
towards modified p53-based peptides. Activity was determined in a luminescence (red) or 
fluorescence (blue) based assay and normalized against wild-type SIRT1CAT activity. Each 
data point represents the mean of at least three independent measurements. Error bars 
represent standard deviations. See also Fig. S5.
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Fig. 7. 
Exchange of the C-terminal regulatory segment. (a) Size-exclusion chromatography 
interaction analysis of the SIRT1CAT•CTR heterodimer with SUMO-CTR. The analyzed 
proteins and complexes are indicated in each gel filtration profile. For analysis of complex 
formation, SUMO-CTR was mixed at approximately 2-fold molar excess and injected onto a 
Superdex 200 10/300 GL gel filtration column. Gray bars and colored lines designate the 
analyzed fractions. Molecular mass standards and the positions of the proteins are indicated. 
Untagged CTR is too small to be visualized on the SDS-PAGE. (b) GST pull-downs of a 
preformed GST-CTR•SIRT1CAT complex with increasing amounts of SUMO-CTR. The 
loaded (top) and pulled-down (bottom) samples are visualized by SDS-PAGE, followed by 
Coomassie brilliant blue staining. As reference, the first two lanes of each gel contain the 
loaded samples of GST-CTR•SIRT1CAT and SUMO-CTR. The relative molar amounts of 
GST-CTR•SIRT1CAT and SUMO-CTR, molecular mass standards and the positions of the 
proteins are indicated. (c) CTR mutational analysis. His-tagged SIRT1CAT and GST-tagged 
CTR variants were coexpressed in E. coli and the resulting soluble lysate fraction was 
analyzed in GST pull-down assays. Samples were visualized by SDS-PAGE, followed by 
Coomassie brilliant blue staining. Molecular mass standards and the positions of the proteins 
are indicated. The asterisk indicates a degraded GST-CTR fragment
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Fig. 8. 
Thermostability assay. (a) SIRT1CAT was incubated alone and in the presence of SUMO-
CTR or a non-interacting SUMO-CTRY650D, I651D mutant at the indicated temperatures for 
one hour and pelleted by centrifugation. Pellet and supernatant fractions were visualized by 
SDS-PAGE, followed by Coomassie brilliant blue staining. Molecular mass standards and 
the positions of the proteins are indicated. (b) Deacetylase activity of SIRT1CAT and the 
SIRT1CAT•CTR heterodimer under normal conditions (red) and following incubation at 37 
°C for approximately 2 hours prior to the assay (blue). Activity was determined in a 
fluorescence-based assay and normalized against wild-type SIRT1CAT activity. Each data 
point represents the mean of at least three independent measurements. Error bars represent 
standard deviations. The loss of deacetylase activity is attributed to the aggregation of the 
catalytic domain.
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Fig. 9. 
Model for the conformational changes and regulation of SIRT1. A cartoon representation of 
the apo SIRT1CAT•CTR heterodimer (left) and the SIRT1CAT•CTR•ADPR•Substrate 
complex (right), colored as in Fig. 1a. Substrate and co-factor binding leads to the closure of 
the SIRT1 catalytic domain. The substrate peptide is primarily bound by backbone 
interactions and the formation of a three-stranded anti-parallel β staple. The hydrophobic 
acetylated lysine substrate residue reaches into the secluded internal active site through the 
hydrophobic tunnel where it is oriented in close proximity to the activated NAD+. In the 
closed state, the CTR forms a salt-bridge with the helical module, thereby reducing the 
efficiency of catalysis.
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Table 1
Crystallographic analysis
Data collection
Protein SIRT1•CTR•ADPR•Substrate SIRT1•CTR apo
PDB code 4KXQ 4IF6
Synchrotron SSRL SSRL
Beamline BL12-2 BL12-2
Space group P3221 P43212
Cell parameters
 a, b, c (Å) 92.7, 92.7, 97.7 115.8, 115.8, 350.5
 α, β, γ (°) 90.0, 90.0, 120.0 90.0, 90.0, 90.0
Zn peak Zn peak
Wavelength (Å) 1.28210 1.2676
Resolution (Å) 50.0 – 1.85 50.0 – 2.65
Rsym (%)b 4.3 (62.6) 8.8 (94.3)
<I>/<σI>b 34.3 (2.4) 18.3 (1.8)
Completeness (%)b 100.0 (99.9) 97.1 (92.8)
No. observations 406,347 541,806
No. unique reflections 80,328 (8,010) 68,583 (6,409)
Redundancy 5.1 (4.7) 7.9 (7.8)
Refinement
Resolution (Å) 50.0 – 1.85 50.0 – 2.65
No. reflections total 80,282 67,954
No. reflections test set 3,824 (4.76%) 1982 (2.92%)
Rwork/Rfree (%) 16.8/18.9 23.0/26.5
No. atoms 2,842 9,424
 Protein 2,484 9,374
 Ligand 47 4
 Water 311 46
B-factors
 Protein 39.4 30.3
 Ligand 33.8 60.6
 Water 45.1 8.2
R.m.s. deviations
 Bond lengths (Å) 0.009 0.002
 Bond angles (°) 1.2 0.630
Ramachandran plotc
 Favored (%) 97.7 96.1
 Additionally allowed (%) 2.3 3.9
 Outliers (%) 0.0 0.0
MolProbity score 1.11 2.04
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aSSRL, Stanford Synchrotron Radiation Lightsource
b
Highest resolution shell is shown in parentheses
cAs determined by MolProbity60
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